Carboxamide GABA-A Receptor Modulators for Selective Anxiolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Benzodiazepines, used as anxiolytics, often come with side effects such as sedation, motor incoordination, abuse liability, and memory impairment, due to their non-selective action on GABAA receptors, which limits their therapeutic potential for anxiety disorders without sedation.
Innovation Solution
Development of compounds with selective agonism for GABAA/α2 receptors, reducing intrinsic efficacy at GABAA/α1 receptors to minimize sedative and motoric side effects while maintaining anxiolytic activity, exemplified by specific phenyl, thienyl, or pyridinyl-based amides that modulate GABAA receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzodiazepines are used as anxiolytics, then anxiolytic effect is achieved, but sedative and motoric side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for specific GABAA receptor subtypes (α2 and α3) rather than acting on all GABAA receptors uniformly. This subtype-selective modulation allows the compound to produce anxiolytic effects through α2/α3 receptor activation while avoiding sedative effects associated with α1 receptor activation, thereby achieving localized therapeutic action with reduced side effects
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of GABAA modulators to alter their binding characteristics. Specifically, the compounds feature distinct molecular structures (with specific substituents R1-R6) that change their receptor interaction parameters, enabling selective binding to α2 and α3 subtypes with high affinity while having low affinity for α1 subtype, thus changing the efficacy parameters across different receptor subtypes
2Reliability
If non-selective GABAA modulators are used, then anxiolytic activity is achieved, but abuse liability increases
Solution Approach 1:
The patent applies local quality by directing the modulatory action specifically to α2 and α3 GABAA receptor subtypes that are implicated in anxiety without involvement in sedation and reward pathways. This selective localization of pharmacological action maintains anxiolytic efficacy while eliminating the abuse liability associated with non-selective agents that activate α1 receptors involved in sedative and rewarding effects
3Reliability
If GABAA/α1-selective compounds are used, then sedative effect is achieved, but motor incoordination occurs
Solution Approach 1:
The patent applies inversion by reversing the conventional approach: instead of selecting for α1 receptors to achieve sedation (as done with zolpidem), the invention selectively targets α2 and α3 receptors. This inverted strategy achieves the opposite outcome - providing anxiolytic effects without the sedative and motor-coordinating side effects that characterize α1-selective compounds
Data Source
AI summary
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.